OCTalks: TONIC-trial yields promising results for metastatic triple-negative breast cancer

In this podcast discover details of the TONIC-trial which has yielded promising response rates in patients with metastatic triple-negative breast cancer treated with nivolumab after induction treatment. This adaptive phase II randomized non-comparative trial allocated patients with metastatic TNBC who received ≤ 3 lines of palliative chemotherapy to one of five 2 week induction treatment arms consisting of either three cycles of 8 Gy irradiation of one metastatic lesion, or two cycles of doxorubicin at 15 mg weekly, or cyclophosphamide at 50 mg daily orally or two cycles of 40 mg/m2 of cisplatin, or to receive no induction treatment.

Marleen Kok The Netherlands Cancer Institute (Amesterdam) presented the findings recently at the ESMO 2017 Congress (8–12th September, Madrid, Spain), listen to the podcast now to discover all the details of the trial and Marleen’s favorite talks from ESMO.